Covid-19 U07.1
Conditions
Interventions
Group 1: Every study participant receives 3 nasopharyngeal swabs. One will be examined by RT-PCR (RIDA®?GENE SARS-CoV-2 Test, R-Biopharm) incl. examination for the mutations N501Y and delH69/V70. The
Roche Diagnostics
Mannheim, Germany, www.roche.com) and Abbott (Abbott Panbio TM COVID-19 Ag Rapid Test, Abbott Rapid Diagnostics Jena GmbH, Jena, Germany, www.abbott.com/poct). Afterwards interview of the study partic
Sponsors
Synlab Academy, Synlab Holding Deutschland GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Subjects eligible for inclusion in this study must meet the following criteria: 1. Signed informed consent must be obtained prior to study participation. The patient must be capable of understanding the nature, significance and implication of the trial. 2. Age 18 years or more
Exclusion criteria
Exclusion criteria: 1. Lack of informed consent 2. Inability to understand the nature, significance and implication of the trial. 3. Severe clinical conditions requiring emergency hospitalization 4. Children and adolescents under the age of 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of SARS-CoV-2 rapid detection tests. 31.03.2021. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity of rapid detection tests for different SARS-CoV-2 variants. 31.12.2021. | — |
Countries
Germany
Contacts
Public ContactWinfried März
Synlab Academy, Synlab Holding Deutschland GmbH
Outcome results
None listed